N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Tight Control of Treatment Adherence and Efficacy by Telemedicine for an Improved Personalized Management of Patients With Hemophilia

Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • ClinicalTrials.gov ID: NCT07867834

Registry updated: 2026-10-09
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

In patients with haemophilia, close monitoring of bleeding with optimal adherence to treatment, a personalised treatment programme and the possibility of early diagnosis of haemarthrosis are essential. The TEMPO project will help advance the state of the art in optimal adherence, rigorous monitoring, and accurate and early diagnosis and management of haemarthrosis by collecting and integrating big data in order to personalise the treatment regimen for each patient, as envisaged by the current model of personalised medicine.

Interventions

  • TEMPO (Other)
    Personalized telemedicine

Eligibility criteria

Inclusion Criteria: * informed consent * age (minimum 18 years) * hemophilia * having a smartphone Exclusion Criteria: * autoimmune, inflammatory or degenerative diseases that cause arthritis

Conditions

Hemophilia

Locations

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico — Milan, Italy
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record